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Abstract
Background: Cerebral microdialysis has been established as a monitoring tool in neurocritically
ill patients suffering from severe stroke. The technique allows to sample small molecules in the
brain tissue for subsequent biochemical analysis. In this study, we investigated the proteomic profile
of human cerebral microdialysate and if the identified proteins might be useful predictors for
disease characteristics in stroke for tissue at risk in the contralateral hemisphere. We analysed
cerebral protein expression in microdialysate from three stroke patients sampled from the
hemisphere contralateral to the lesion. Using a proteomic approach based on two-dimensional gel
electrophoresis and subsequent mass spectrometry, we created a protein map for the global
protein expression pattern of human microdialyste.
Results:  We found an average of 158 ± 24 (N = 18) protein spots in the human cerebral
microdialysate and could identify 95 spots, representing 27 individual proteins. Most of these have
been detected in human cerebrospinal fluid before, but 10 additional proteins mainly of cerebral
intracellular origin were identified exclusively in the microdialysate.
Conclusions: The 10 proteins found exclusively in human cerebral microdialysate, but not in
cerebrospinal fluid, indicate the possibility to monitor the progression of the disease towards
deterioration. The correlation of protein composition in the human cerebral microdialysate with
the patients' clinical condition and results of cerebral imaging may be a useful approach to future
applications for neurological stroke diagnosis, prognosis, and treatment.
Background
Microdialysis is used to monitor changes in the composi-
tion of the extracellular fluid in living tissue, measuring
the concentrations of small molecules such as neurotrans-
mitters, hormones, ions, or peptides [1-3]. In principle,
molecules up to a certain molecular weight cross the semi-
permeable probe membrane and are collected in the efflu-
ent microdialysate, depending on the concentration gra-
dient, the flow velocity of the perfusate, the diffusion
coefficients of the molecules, and the permeability of the
membrane [1-3]. In the brain, the perfusion fluid is com-
posed of "artificial" CSF, containing ions in the same con-
centration as in CSF in vivo [1], thus the concentrations of
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molecules found in the microdialysate represent their
concentration in the brain tissue.
We have established microdialysis as a monitoring tool
for neurotransmitter release and metabolic products in
critically ill stroke patients during their intensive care
management [4,5]. In these studies, the tissue at risk can
be monitored with regard to its metabolic status, or cellu-
lar damage of the brain by microdialysis and intracranial
temperature and pressure measurement in co-interpreta-
tion with neuroradiological imaging. The main factor of
high diagnostic and prognostic value will need to predict
a possibility to rescue the function of the remaining, non-
diseased brain tissue, even more importantly, if the infarct
core might still be growing towards the penumbral tissue.
Therefore, we were interested in the present study in the
protein expression profile of human brain microdialysate,
as the proteins found in the microdialysate might be
related to metabolic status and cellular damage as indica-
tor for the tissue at risk.
Although microdialysis is an important method in moni-
toring neurological disease, studies investigating protein
expression patterns of microdialysate have not been per-
formed yet, but cerebrospinal fluid has been extensively
analysed by two-dimensional gel electrophoresis (review
in [6]), and about 30–35 different proteins have been
identified so far. Two-dimensional gel electrophoresis is a
useful instrument to search for changes in the cerebrospi-
nal fluid protein expression pattern in neurological and
psychiatric diseases, but it cannot follow the time-course
of the disease, as it represents a static measurement at a
single given time-point. Moreover, the composition of
normal cerebrospinal fluid differs markedly from the
composition of extracellular fluids in the brain, including
microdialysate [7]. Here, we present for the first time a
protein map that is derived from microdialysate of non-
infarcted brain tissue of three stroke patients.
Results
We analysed human brain microdialysate obtained from
the contralateral, non-infarcted hemisphere of three
stroke patients to create a two-dimensional protein map
of microdialysate (Fig. 1). The average protein content in
the microdialysis samples of the three patients was 0.21 ±
0.11 g/L, ranging from 0.083 to 0.395 g/L (N = 18, six
samples for each patient) which is comparable to CSF (0.2
g/L) [8]. This protein concentration allowed us to use the
microdialysate in the two-dimensional gel electrophoresis
experiments without further processing or concentration
steps.
We separated individual proteins within the cerebral
microdialysate by two-dimensional gel electrophoresis
according to their isoelectric point and their molecular
weight, subsequently followed by mass spectrometry, gel
matching and database search to identify the proteins. We
found an average of 158 ± 24 (N = 18, six samples for each
patient) protein spots in the two-dimensional electro-
phoresis gels. Of the mapped protein spots, we could
identify 95 spots by mass spectrometry and database
search, representing 27 individual proteins or protein
groups (Table 1). Of these, we have found 10 proteins
exclusively in the microdialysate, whereas 17 proteins
have been described earlier for cerebrospinal fluid [9]. The
95 protein spots included different isoforms and post-
translational modifications of the proteins, e. g. glycosyla-
tion, to alter molecular weight and/or isoelectric point.
Unfortunately, it was not possible to obtain mass spec-
trometry sequence data to reliably identify the missing
protein spots.
Discussion
Human brain microdialysis
This is the first report on cerebral microdialysis in the
human brain analysed by a proteomic approach based on
two-dimensional gel electrophoresis and mass spectrom-
etry that describes the molecular pattern of protein expres-
sion in the brain microdialysate of three stroke patients.
We hope to provide a proteome map for human brain
microdialysate which allows both future comparisons
between microdialysate samples from different stages of
the disease, and between microdialysate and CSF.
In clinical practice, microdialysis has become a useful
monitoring technique to detect the development of sec-
ondary neuronal ischemia and to assess the potential
reversibility of ischemic brain damage [10]. It may be
more sensitive than other diagnostic instruments as EEG
and somatosensory evoked potentials, however, the
method is invasive, and positioning the probes into
penumbral tissue, or into the infarct core, may be difficult
even with advanced neuroradiological methods, as the
microdialysis probes are not radiopaque and the target
volume is very small. Thus a direct measurement in the
infarct core, or penumbral tissue, is technically difficult
and limited in its diagnostic and prognostic value. On the
other hand, it may be even more interesting to determine
the metabolic status of not yet infarcted tissue at risk of
ischemia. Therefore the implantation of a microdialysis
probe in the non-infarcted hemisphere may contribute to
the prognostic monitoring of the non-diseased hemi-
sphere to indicate possible necessary therapeutical inter-
vention, like craniotomy, hypothermia etc. We have
already established this monitoring for small molecules
like neurotransmitters and metabolites [4,5,11] during
hypothermic treatment, where microdialysis allowed to
assess the patient's current status and to predict further
deterioration which is subsumed as "malignant" cerebral
infarction. Therefore, we were interested in the presentProteome Science 2003, 1 http://www.proteomesci.com/content/1/1/7
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Schematic principle of microdialysate sampling and two dimensional electrophoresis Figure 1
Schematic principle of microdialysate sampling and two dimensional electrophoresis. Following the parietal 
implantation of the microdialysis catheter, a small volume of microdialysate is collected. The microdialysate sample is subjected 
two-dimensional gel electrophoresis with first dimension IEF and second dimension SDS-PAGE. Gels were stained and individ-
ual protein spots were analysed by mass spectrometry.Proteome Science 2003, 1 http://www.proteomesci.com/content/1/1/7
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study in the protein expression pattern of human brain
microdialysate, as the proteins found in the microdia-
lysate might give insight into the metabolic status and cel-
lular damage of the brain.
With regard to protein recovery, we found that the pre-
dicted cut-off value of the dialysis membrane of 20 kDa
could not prevent even high-molecular weight proteins
(up to 180 kDa) from passing through the membrane.
The cut-off is defined as the molecular weight at which
80% of the molecules are prevented from passing through
the dialysis membrane [12]. This means that molecules
larger than 20 kDa are not excluded from the microdia-
lysate, but their presence is more unlikely, or their concen-
tration in the sample is smaller than in the extracellular
fluid. The term protein recovery describes the protein con-
centration found in the microdialysate compared to the
brain extracellular fluid. Protein recovery depends on the
length and diameter of the membrane, the flow rate of the
perfusion fluid, temperature and pH, molecular weight,
shape, and charge of the molecules influencing the diffu-
sion coefficient, and the binding of the proteins to the
membrane and the tubing, and possible degradation of
the proteins [13-15]. In our interpretation, the specific
geometry of the custom-made microdialysis membrane
(diameter 0.65 mm, length 10 mm) could contribute to
the finding of proteins larger than the formal cut-off of 20
kDa.
Microdialysis in stroke patients
Extensive brain infarction and subsequent brain edema
formation are neurological disorders requiring intensive
care treatment but still present a mortality of up to 80%
[16]. Various treatment measures, such as osmotic agents,
craniotomy, and hypothermia, have been investigated to
minimize brain edema, reduce mortality, and improve
outcome. However, monitoring the efficacy of these meas-
ures is often difficult, especially with regard to early prog-
Table 1: Proteins identified in the human cerebral microdialysate. The upper part contains proteins also found in CSF, the lower part 
lists additional proteins found in the microdialysate which have not been described in CNS. The first column gives the consecutive 
number of the identified protein, the second column the number of spots in the two-dimensional gels belonging to the individual 
proteins. The third and fourth column displays the protein annotation as in the SwissProt database at http://www.expasy.ch. The amino 
acid composition or structural information about the proteins can be retrieved via the accession number in the fifth column. This 
database also contains the CSF protein map. The sixth and seventh column shows pI and molecular weight. Strictly speaking, the 
immunoglobulin fractions do not represent a single protein, but a protein family, therefore pI and molecular weight cannot be given.
Spot number Number of spots 
identified
Gene name Protein description SwissProt accession 
number
Theoretical pI Theoretical molecular 
weight (Da)
proteins identified in cerebral microdialysate and cerebrospinal fluid
1 8 SERPINA3 Alpha-1-antichymotrypsin P01011 5.33 47651
2 8 SERPINA1 Alpha-1-antitrypsin P01009 5.37 46737
3 5 A1BG Alpha-1B-glycoprotein P04217 5.65 51941
4 3 APOA1 Apolipoprotein A-I P02647 5.56 30778
5 1 AMBP AMBP protein P02760 5.95 38999
6 2 APOE Apolipoprotein E P02649 5.65 36154
7 2 C3 Complement C3 P01024 6.02 187164
8 1 FGG Fibrinogen gamma chain P02679 5.37 51512
9a 6 HP Haptoglobin-2 P00738 6.13 45205
9b 2 HP Haptoglobin alpha-2 chain P00738 5.57 15946
9c 2 HP Haptoglobin beta chain P00738 6.32 27265
10 7 -- Immunoglobulin heavy chain P99006 -- --
11 13 -- Immunoglobulin light chain P99007 -- --
12 1 RBP4 Plasma retinol-binding protein P02753 5.76 23044
13 4 PLG Plasminogen (EC 3.4.21.7) P00747 7.04 90569
14 5 ALB Albumin P02768 5.92 69367
15 5 TF Transferrin P02787 6.81 77050
16 2 TTR Transthyretin P02766 5.52 15887
17 2 GC Vitamin D-binding protein P02774 5.24 56761
proteins identified solely in cerebral microdialysate
18 1 B2M Beta-2 microglobulin P01887 7.80 13823
19 1 CKB Creatine kinase, B chain P12277 5.34 43644
20 1 DRP2 Dihydropyrimidinase related protein-2 Q16555 5.95 62294
21 4 GAPD Glyceraldehyde 3-phosphate dehydrogenase P16858 8.45 35679
22 1 HSP73 Heat shock protein 70 kD HSP73 P11142 5.37 70898
23 1 HBB Hemoglobin beta chain P02023 6.81 15867
24 1 MDHA Malate dehydrogenase P40925 6.89 36295
25 4 TUBA1 Tubulin alpha-1 P04687 4.94 50152
26 3 -- Tubulin beta Q13885 4.78 49907
27 1 TUBB5 Tubulin beta 5 Q8WUC1 4.78 49671Proteome Science 2003, 1 http://www.proteomesci.com/content/1/1/7
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nostic detection of severe neuronal damage. Microdialysis
was developed for neurochemical monitoring and allows
measurement of the extracellular concentrations of vari-
ous endogenous substances, such as excitotoxic amino
acids or metabolic end products in short sampling periods
of time [2,17,18].
We are aware that there is no "physiological" microdia-
lysate, because obtaining microdialysate from non-dis-
eased volunteers is ethically not practicable and rises
major concerns. With regard to the literature, we want to
point out that all  published microdialysate studies for
human brain tissue were performed in patients, not vol-
unteers, where these subjects suffered from severe neuro-
logical deficits, and received a number of treatments,
including craniotomy, or hypothermia. Thus we must
emphasize that the proteome map of human brain micro-
dialysate as presented here, is collected from non-diseased
brain tissue in stroke patients under intensive care condi-
tions and hypothermia. Whether these conditions influ-
ence the proteome profile, is unknown.
The patients described in this study showed the clinical
and neuroradiological features of a space-occupying hem-
ispheric stroke. CT scan demonstrated extensive brain inf-
arction with severe initial mass effects. Brain edema was
treated with hypothermia and osmotic agents, which
decreased the edema volume. Hypothermia was consid-
ered an experimental rescue therapy, although evidence is
increasing that moderate hypothermia is a potent meas-
ure to treat brain edema [4]. Neurochemical analysis of
small molecules and metabolites sampled from the non-
infarcted hemisphere and processed using a HPLC system
showed normal values for glutamate (3.9 ± 0.3 µmol/L),
glycerol (38.9 ± 1.9 µmol/L), lactate (2.0 ± 0.1 mmol/L),
and pyruvate concentrations (58.4 ± 3.3 µmol/L) over the
sampling period of 18–72 hours [19]. These results indi-
cate that there is no increased cell death and glutamate
release in the non-infarcted hemisphere, and that the non-
infarcted hemisphere is still not affected by ischemia.
Proteomic approach and comparison to CSF
In recent years, proteomic approaches have been devel-
oped as mass screening tools to evaluate protein expres-
sion patterns in various tissues and body fluids [9,20].
Cerebrospinal fluid (CSF) has been extensively analysed
by two-dimensional gel electrophoresis (2-DE) [21-23],
and about 30–35 different proteins have been identified
so far. 2-DE proofed to be a useful tool to search for
changes in the CSF protein expression pattern in neuro-
logical and psychiatric diseases [24], but CSF analysis can-
not follow the time-course of the disease, as it represents
a static measurement at a single given time-point. The
knowledge of the time-course and appearance or disap-
pearance of certain proteins might be useful for prediction
of the progression of the disease. Therefore, the combina-
tion of microdialysis and proteomics may be a useful
instrument.
In the proteomic approach applied in this study, we found
an expression pattern of the microdialysate proteins
which differed markedly from human cerebrospinal fluid,
but most of the proteins identified in the microdialysate
have also been detected in cerebrospinal fluid [9,25]. We
could identify 95 spots out of an average of 158 (60%) in
the two-dimensional gels, representing 27 individual pro-
teins. Due to isoforms and protein modifications such as
glycosylation, phosphorylation, etc. the number of pro-
teins actually found is lower than the number of protein
spots. Mass spectra producing ambiguous results indicat-
ing that there might be 2 or more proteins present in a sin-
gle spot, did not allow to identify the protein spot
precisely, therefore it was classfied as "unindentified" in
this study.
Functional role of the identified proteins
Most of the identified proteins have also been detected in
human CSF, as the perfusion solution and therefore the
brain microdialysate is composed mostly of CSF, or "artif-
ical" CSF [7,9,25]. We found 10 additional proteins,
which were mainly of intracellular origin (Table 1, lower
part). Of these, creatine kinase B subunit and tubulin
alpha-1 were brain-specific proteins, indicating that these
proteins are not of intravascular, circulatory, or CSF ori-
gin. When comparing the human CSF map to the human
microdialysate map, the differences found could be attrib-
uted to the composition of microdialysate as an filtrate of
CSF, but the additional proteins (Table 1, lower part) may
enable the monitoring of brain function and brain cell sta-
tus in vivo in a future application. It would be a desirable
aim to have a diagnostic or prognostic tool for early detec-
tion of "malignant" cerebral infarction, which, as opposed
to non-malignant cerebral infarction, needs a different
type and intense of treatment.
The 10 proteins found exlusively in microdialysate, not in
CSF, are unlikely to be the result of tissue injury due to the
microdialysis probe as microdialysate sampling did not
begin until 18 hours after probe insertion. Furthermore,
since the stroke patients show imaging evidence of edema
formation that may be compromising perfusion in the
contralateral hemisphere and inducing tissue injury, these
proteins may indeed be coming from the ipsilateral hem-
isphere that is undergoing injury. Their appearance could
also be the result of tissue compression and developing
injury in the contralateral hemisphere due to the expand-
ing edema formation.
We found proteins in the microdialysate which are
located intracellularly under physiological conditions.Proteome Science 2003, 1 http://www.proteomesci.com/content/1/1/7
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There might be several explanations for their appearance
in the microdialysate: (1) A large number of cells might be
compromised in the non-stroke lesioned hemisphere,
indicating that the tissue in the hemisphere contralateral
to the stroke is already at risk of becoming lesioned. (2)
The proteins originate from the lesioned hemisphere, but
the ways of transport remain unknown. The appearance of
many CSF proteins may also indicate a lesion of the
blood-brain barrier, but the similarity of microdialysate
and CSF is more likely explained by the contribution of
CSF as major component of the extracellular fluid to the
sampling process of microdialysis. (3) The implantation
of the microdialysis probe contributes to this finding by
lesioning tissue in the contralateral hemisphere.
The functional role of the 10 proteins identified exclu-
sively in the microdialysate (Table 1, lower part) is known
from the biochemical pathways they are integrated in.
However, as we learn more about function and location of
proteins, there is a reappraisal in some functional aspects
of proteins: A protein does not only have a single func-
tion, indeed most proteins seem to have several functions,
e. g. in transport, regulation of enzyme activity, or activa-
tion of biological systems, depending on the protein's
location and the microenvironmental conditions. For
example, hemoglobin which we have found in the micro-
dialysate, does not only transport oxygen and carbon
dioxide but also plays a role as a potent NO detoxifier and
oxygen scavenger, in addition to the regulation of blood
pH and of regional blood flow [26,27].
Conclusions
The first step in this research program was to provide a
proteome map in human cerebral microdialysate. Based
on these mapping data, future investigations will focus on
the biological meaning of the identified proteins as valu-
able markers for diagnosis and prognosis, or even thera-
peutical approach. The combination of microdialysis,
two-dimensional gel electrophoresis, and mass spectrom-
etry revealed a characteristic spot pattern for human cere-
bral microdialysate and is an applicable method to
analyse this body fluid. Ten proteins have been found in
the microdialysate which have not been observed in CSF.
Most of the proteins found exclusively in the microdia-
lysate are of intracellular origin, indicating a relationship
between protein concentration in the microdialysate and
tissue damage. The different samples (6 each in 3
patients) showed a high reprocibility. Unfortunately, the
limited number of samples did not allow to conduct time-
course analysis due to statistical reasons. To draw conclu-
sions with regard to differential analysis of protein con-
centrations, a larger number of patients has to be
analysed. In principle, it would also be of interest to mon-
itor the time-course of protein spot patterns in neurologi-
cal diseases, such as stroke. The possible correlation of
concentrations of certain proteins in the human cerebral
microdialysate with the patients' clinical condition and
with the results of the cerebral imaging (CCT, MRI) may
be a useful approach to future applications for neurologi-
cal stroke diagnosis and treatment.
Patients and methods
Flexible microdialysis probes with a formal cut-off level of
20 kDa (membrane diameter 0.65 mm, membrane length
10 mm) (CMA/70 custom probes, CMA Microdialysis,
Solna, Sweden) and an intracranial pressure measuring
device (Spiegelberg, Hamburg, Germany) were inserted
into the fronto-parietal parenchyma of three patients with
severe hemispheric stroke. Microdialysate in the present
study was collected from the non-diseased, contralateral
hemisphere. All patients were part of an open, prospective
observational study [4] on neurochemical monitoring of
brain tissue that was approved by the local Ethics Com-
mittee (approval number 34/97) and required written
consent by the patient's next of kin according to the Dec-
laration of Helsinki. Patients were male and aged 32, 42,
and 63. Initial CCT and MRI scan demonstrated complete
infarction of the left middle cerebral artery territory with
attenuated hemispheric perfusion and impending mass
effect due to edema formation. We included patients with
a hypodensity in the initial CT scan exeeding two thirds of
the MCA territory. Developing brain edema on CT was
diagnosed by hypodensity and midline shift. Midline shift
was considered significant when reaching more than 1
cm. MRI showed hypointense signals in the MCA territory
and a matching deficit in the diffusion- and perfusion-
weighted images. The penumbral zone was defined by the
area of a perfusion-diffusion mismatch. The patients were
analgosedated, mechanically ventilated and were treated
initially with mild hypothermia (33°C) as rescue therapy.
All three patients passed away after several days of inten-
sive care treatment due to their severe brain damage.
Microdialysis was performed as described [4,5,11].
Briefly, the microdialysis probes were perfused at 0.3 µL/
min with a sterile CSF equivalent solution consisting of
147 mmol/L NaCl, 2.7 mmol/L KCl, 1.2 mmol/L CaCl2,
and 0.85 mmol/L MgCl2  (CNS perfusion fluid, CMA
Microdialysis, Solna, Sweden).
Microdialysis fluid was sampled in vials replaced every 60
to 120 min. The samples used in this study were obtained
in a timecourse of 18–72 h after implantation of the
microdialysis probes. After immediate neurochemical
analysis, vials were stored at -20°C for post hoc proteome
analysis. Total protein content in the undiluted microdi-
alysis samples was measured by the MicroBCA assay
(Pierce, Rockford, Illinois, U.S.A.).Proteome Science 2003, 1 http://www.proteomesci.com/content/1/1/7
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Two-dimensional gel electrophoresis was performed
essentially in accordance with standard protocols [28,29]
and as described previously in detail [30]. Briefly, micro-
dialysate samples were centrifugated for 5 min at maxi-
mum speed on a table centrifuge to remove disturbing
substances such as cell debris. 5–10 µL (corresponding to
1–2 µg) of the microdialysate were suspended in 6 M urea,
2 M thiourea, 2% CHAPS, 0.5% IPG buffer pH 3–10
(Amersham Biosciences, Uppsala, Sweden), and a trace of
bromophenol blue, resulting in a final volume of 350 µL.
Samples were applied to pH 3–10 non-linear gradient iso-
electric focussing gel strips (Immobiline DryStrip pH 3–
10 NL, 18 cm) in the IPGphor apparatus (both Amersham
Biosciences, Uppsala, Sweden) with 12 hours of reswell-
ing at 30 V, then 200 V, 500 V, and 1,000 V for 1 hour
each. Voltage was increased to 8,000 V in 30 min and kept
Two-dimensional electropherogram of human microdialysate Figure 2
Two-dimensional electropherogram of human microdialysate. This figure shows a real image sample of a cerebral 
microdialysate electrophoresis gel with annotated gel spots. We found an average of 158 ± 24 protein spots in the gels (N = 
18), of which 95 could be identified by subsequent mass spectrometry and database search, representing 27 different proteins.Proteome Science 2003, 1 http://www.proteomesci.com/content/1/1/7
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constant at 8,000 V for 12 hours, resulting in a total of
100,300 Vh. The gel strips were equilibrated for 20 min
each in 1% dithiothreitol or 2.5% iodoacetamide, respec-
tively, followed by a non-gradient, 12.5% polyacrylamide
gel electrophoresis in the presence of 0.1% sodium
dodecyl sulfate. Gels were run at 30 mA for 30 min and
100 mA for about 4 h in a 20 cm × 20 cm water-cooled
vertical electrophoresis apparatus. Six gel electrophoresis
replicates were run for each patient.
For image analysis, gels were silver stained [31] and digi-
tized in a desktop scanner. Images were analysed densito-
metrically by the Phoretix 2D Elite software (Nonlinear
Dynamics, Newcastle-upon-Tyne, UK), and gel matching
was performed as described [30].
For mass spectrometry, gels were stained using colloidal
Coomassie Brilliant Blue [32]. Spots of interest were
excised, and mass spectrometry and data acquisition were
performed by the mass spectrometry group of the Univer-
sity of Heidelberg's Center for Molecular Biology (ZMBH)
using MALDI-TOF mass spectrometry (Reflex III, Bruker
Daltonics, Bremen, Germany) instrumentation. Mass
spectra were compared to the Mascot database http://
www.matrixscience.com[33] to identify peptide
sequences.
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